Every 10-Q that Zai Lab Limited (ZLAB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ZLAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZLAB filings page.
Zai Lab reported second-quarter 2026 total revenues of $106.3 million, down modestly from the prior year, with net product revenue of $105.8 million. The company posted a net loss of $50.8 million, or $0.05 per ordinary share, as higher research and development spending offset revenue.
ZEJULA revenue declined as hospital utilization shifted following volume-based procurement for generic olaparib and VYVGART faced pricing adjustments tied to NRDL renewal, while XACDURO and NUZYRA delivered growth. Research and development expenses rose to $61.8 million, driven by increased upfront and milestone licensing fees.
Pipeline and regulatory progress was significant: Zai Lab launched KarXT for schizophrenia in mainland China and secured China approval for TIVDAK in recurrent or metastatic cervical cancer. Zoci (DLL3-targeting ADC) showed notable response rates in SCLC and extrapulmonary NECs and received FDA Fast Track and U.S./EU orphan designations. Cash, current restricted cash, and short-term investments totaled $717.5 million at June 30, 2026, which management expects to fund operations for at least the next 12 months.
Zai Lab Limited reported first-quarter 2026 revenue of $99.6 million, with net product revenue of $95.6 million, down 10% year over year, and a net loss of $51.0 million (loss of $0.05 per ordinary share).
Sales declined mainly because ZEJULA revenue fell 39% to $30.0 million after volume-based procurement for generic olaparib, and VYVGART revenue softened following a pricing adjustment tied to NRDL renewal. These pressures were partly offset by strong growth from XACDURO, whose revenue rose to $8.6 million, and continued gains from NUZYRA and OPTUNE.
The company increased research and development spending to $65.6 million, driven by higher clinical trial and licensing costs, while selling, general, and administrative expenses rose modestly to $65.1 million. Zai Lab ended the quarter with $761.3 million in cash, cash equivalents, current restricted cash, and short-term investments and $213.8 million in short-term debt, supporting ongoing late-stage programs and new collaborations highlighted in oncology and immunology.
Zai Lab Limited reported Q3 2025 results showing higher sales and a narrower loss. Total revenues were $116.1 million (up 14% year over year), driven by net product revenue of $115.4 million. The company posted a net loss of $36.0 million, improving from a $41.7 million loss a year ago, with basic and diluted loss per share of $0.03.
Growth was led by NUZYRA $15.4M (+54% YoY), OPTUNE $12.7M (+64% YoY), and contributions from XACDURO $6.4M and AUGTYRO $1.7M, while ZEJULA $42.4M declined 12% amid class competition. R&D expenses fell to $47.9M (down 27%), reflecting lower licensing fees, and SG&A was $70.1M. Cash and cash equivalents were $717.2 million as of September 30, 2025; short‑term debt was $203.0 million. Shares outstanding were 1,105,937,600 as of October 31, 2025.
Zai Lab Limited (ZLAB) Q2 2025 10-Q highlights: Net product revenue rose 9 % YoY to $109.1 million, lifting total revenue to $110.0 million. Cost controls drove a 28 % YoY cut in operating loss to $54.9 million and shrank net loss by 49 % to $40.7 million (-$0.04/share). Six-month revenue climbed 15 % to $216.5 million, with net loss down 33 % to $89.2 million.
Growth came from VYVGART (+14 %), NUZYRA (+16 %), XACDURO and AUGTYRO launches, partly offset by a 9 % decline in ZEJULA. R&D expense fell 18 % YoY, SG&A fell 11 %, and operating cash outflow improved to -$92.7 million from -$132.3 million. Cash & equivalents surged to $732.2 million after maturing $330 million of short-term investments; short-term debt increased to $174.5 million (2.66 % avg. rate).
- Q2 gross margin ~61 % (product revenue vs. cost of product revenue).
- Shares outstanding: 1.10 billion; ADS float 421.7 million.
- Pivotal pipeline events: Fast Track for ZL-1310 (SCLC), positive Phase III data for bemarituzumab (FGFR2b gastric), PANOVA-3 success for TTFields, NMPA sNDA acceptance for repotrectinib.
- Subsequent event: doubled CMB revolving facility to RMB500 million (~$69.6 million) on 6 Aug 2025.
Despite stronger top-line momentum and disciplined spending, Zai Lab remains loss-making and dependent on capital markets and credit lines while advancing an expansive late-stage pipeline.